<DOC>
	<DOCNO>NCT00317915</DOCNO>
	<brief_summary>The aim multicenter , doubleblind , randomize study investigate renoprotective effect irbesartan treatment patient type 2 diabetes microalbuminuria ( precursor diabetic kidney disease ) . 590 patient randomized median 24 month treatment 300 mg irbesartan daily , 150 mg irbesartan daily placebo . Time development overt nephropathy , define persistent proteinuria , primary outcome measure .</brief_summary>
	<brief_title>Irbesartan Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Type 2 diabetes . Hypertension . Persistent microalbuminuria . Serum creatinine concentration 1.5 mg per deciliter ( 133 µmol per liter ) men 1.1 mg per deciliter ( 97 µmol per liter ) woman . Nondiabetic kidney disease . Cancer . Lifethreatening disease death expect occur within two year . Indication angiotensinconverting– enzyme ( ACE ) inhibitor angiotensinII–receptor antagonist .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>